AI & Data
Exalítica
Undisclosed valuation — first AI company acquired in South America
Track record
Built by founders and operators who have created, scaled, financed and sold companies.
The mid-market doesn't need more intermediation; it needs institutional preparation, intelligent buyer mapping and senior execution.
AI-driven execution
AI native to how we operate.
We use it to compress timelines, deepen analysis, and uncover patterns that traditional research misses.
−75%
Research time
Documented reduction in time-to-insight across buyer mapping, sector benchmarking, and target screening — via Zion Signal, our screening and propensity model.
Native
AI agents
Custom agents engineered for sector research, comparable analysis, and value-driver pattern detection — reducing overhead and accelerating execution.
Audited
Due diligence
AI-supervised diligence reviews stress-test findings, flagging gaps human review can miss.
AI accelerates the process. Relationships still close the deal.
Sector focus
Where dealflow, demand and premium converge.
- 01
Technology & SaaS
Vertical software and IT services in Chile and Mexico — the strongest buyer universe and AI tailwind.
- 02
Fintech
Digital infrastructure, payments, wealth and lending — global investor appetite, regional consolidation.
- 03
Healthcare
Clinical diagnostics, biotech, services — premium multiples for assets with regional scale.
- 04
eCommerce
Marketplaces, brands, and enabling infrastructure — selective, but high-quality assets command premium.
- 05
Supply Chain & Logistics
Industrial, logistics, nearshoring beneficiaries — tied to the recovery in trade.
Geographic coverage
Originating in LATAM. Monetizing globally.
We originate from Santiago, execute across LATAM, and monetize globally. The graphic summarizes Zion's operational footprint and the capital hubs we reach.
Selected transactions
Real outcomes. Real founders. Real exits.
Three engagements representative of Zion's reach across sectors, transaction types and counterparties. Full detail on the dedicated page.
Clinical Diagnostics & Biotech
Galénica
7.1x EBITDA exit multiple
Fintech
Refy
Assets divested in 2025
Let's discuss your next process.